Back to results
CompletedPhase 1

Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

NCT00252850

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

University of California, San Francisco

San Francisco, California, United States

+1 additional location

View on ClinicalTrials.gov
Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease — TrialFind